Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Identification and enhancement of HLA-A2.1-restricted CTL epitopes in a new human cancer antigen-POTE.

Huang YH, Terabe M, Pendleton CD, Stewart Khursigara D, Bera TK, Pastan I, Berzofsky JA.

PLoS One. 2013 Jun 4;8(6):e64365. doi: 10.1371/journal.pone.0064365. Print 2013.

2.

Possible therapeutic vaccine strategy against human immunodeficiency virus escape from reverse transcriptase inhibitors studied in HLA-A2 transgenic mice.

Okazaki T, Terabe M, Catanzaro AT, Pendleton CD, Yarchoan R, Berzofsky JA.

J Virol. 2006 Nov;80(21):10645-51. Epub 2006 Aug 18.

3.

Protective immunity provided by HLA-A2 epitopes for fusion and hemagglutinin proteins of measles virus.

Oh S, Stegman B, Pendleton CD, Ota MO, Pan CH, Griffin DE, Burke DS, Berzofsky JA.

Virology. 2006 Sep 1;352(2):390-9. Epub 2006 Jun 15.

4.

Epitope enhancement of a CD4 HIV epitope toward the development of the next generation HIV vaccine.

Okazaki T, Pendleton CD, Sarobe P, Thomas EK, Iyengar S, Harro C, Schwartz D, Berzofsky JA.

J Immunol. 2006 Mar 15;176(6):3753-9.

6.

Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome.

Carbone DP, Ciernik IF, Kelley MJ, Smith MC, Nadaf S, Kavanaugh D, Maher VE, Stipanov M, Contois D, Johnson BE, Pendleton CD, Seifert B, Carter C, Read EJ, Greenblatt J, Top LE, Kelsey MI, Minna JD, Berzofsky JA.

J Clin Oncol. 2005 Aug 1;23(22):5099-107. Epub 2005 Jun 27.

7.

Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells.

Oh S, Terabe M, Pendleton CD, Bhattacharyya A, Bera TK, Epel M, Reiter Y, Phillips J, Linehan WM, Kasten-Sportes C, Pastan I, Berzofsky JA.

Cancer Res. 2004 Apr 1;64(7):2610-8.

8.

Epitope-enhanced conserved HIV-1 peptide protects HLA-A2-transgenic mice against virus expressing HIV-1 antigen.

Okazaki T, Pendleton CD, Lemonnier F, Berzofsky JA.

J Immunol. 2003 Sep 1;171(5):2548-55.

9.

Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations.

Worley BS, van den Broeke LT, Goletz TJ, Pendleton CD, Daschbach EM, Thomas EK, Marincola FM, Helman LJ, Berzofsky JA.

Cancer Res. 2001 Sep 15;61(18):6868-75.

10.

Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections.

Berzofsky JA, Ahlers JD, Derby MA, Pendleton CD, Arichi T, Belyakov IM.

Immunol Rev. 1999 Aug;170:151-72. Review.

PMID:
10566149
11.

The importance of pairwise interactions between peptide residues in the delineation of TCR specificity.

Leggatt GR, Hosmalin A, Pendleton CD, Kumar A, Hoffman S, Berzofsky JA.

J Immunol. 1998 Nov 1;161(9):4728-35.

12.

Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions.

Sarobe P, Pendleton CD, Akatsuka T, Lau D, Engelhard VH, Feinstone SM, Berzofsky JA.

J Clin Invest. 1998 Sep 15;102(6):1239-48.

13.
14.

Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence.

Ahlers JD, Takeshita T, Pendleton CD, Berzofsky JA.

Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10856-61.

15.

Oncogenic mutations in ras create HLA-A2.1 binding peptides but affect their extracellular antigen processing.

Smith MC, Pendleton CD, Maher VE, Kelley MJ, Carbone DP, Berzofsky JA.

Int Immunol. 1997 Aug;9(8):1085-93.

PMID:
9263005
16.

Reciprocal cytotoxic T lymphocyte cross-reactivity interactions between two major epitopes within HIV-1 gp160.

Shirai M, Kurokohchi K, Pendleton CD, Arichi T, Boyd LF, Takahashi H, Margulies DH, Berzofsky JA.

J Immunol. 1996 Nov 15;157(10):4399-411.

PMID:
8906815
17.

Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-envelope protein to human cytotoxic T lymphocytes.

Alexander-Miller MA, Parker KC, Tsukui T, Pendleton CD, Coligan JE, Berzofsky JA.

Int Immunol. 1996 May;8(5):641-9.

PMID:
8671651
18.
19.

Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region.

Kurokohchi K, Akatsuka T, Pendleton CD, Takamizawa A, Nishioka M, Battegay M, Feinstone SM, Berzofsky JA.

J Virol. 1996 Jan;70(1):232-40.

20.

Molecular analysis of the same HIV peptide functionally binding to both a class I and a class II MHC molecule.

Takeshita T, Takahashi H, Kozlowski S, Ahlers JD, Pendleton CD, Moore RL, Nakagawa Y, Yokomuro K, Fox BS, Margulies DH, et al.

J Immunol. 1995 Feb 15;154(4):1973-86.

PMID:
7530749
21.

An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans.

Shirai M, Okada H, Nishioka M, Akatsuka T, Wychowski C, Houghten R, Pendleton CD, Feinstone SM, Berzofsky JA.

J Virol. 1994 May;68(5):3334-42.

22.

Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs.

Shirai M, Pendleton CD, Ahlers J, Takeshita T, Newman M, Berzofsky JA.

J Immunol. 1994 Jan 15;152(2):549-56.

PMID:
8283036
23.

Multiple pathways are involved in the extracellular processing of MHC class I-restricted peptides.

Kozlowski S, Corr M, Shirai M, Boyd LF, Pendleton CD, Berzofsky JA, Margulies DH.

J Immunol. 1993 Oct 15;151(8):4033-44.

PMID:
8409383
24.

A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells.

Yanuck M, Carbone DP, Pendleton CD, Tsukui T, Winter SF, Minna JD, Berzofsky JA.

Cancer Res. 1993 Jul 15;53(14):3257-61.

26.

The importance of dominant negative effects of amino acid side chain substitution in peptide-MHC molecule interactions and T cell recognition.

Boehncke WH, Takeshita T, Pendleton CD, Houghten RA, Sadegh-Nasseri S, Racioppi L, Berzofsky JA, Germain RN.

J Immunol. 1993 Jan 15;150(2):331-41.

PMID:
8093457
27.

Induction of cytotoxic T cells to a cross-reactive epitope in the hepatitis C virus nonstructural RNA polymerase-like protein.

Shirai M, Akatsuka T, Pendleton CD, Houghten R, Wychowski C, Mihalik K, Feinstone S, Berzofsky JA.

J Virol. 1992 Jul;66(7):4098-106.

28.

Serum angiotensin-1 converting enzyme activity processes a human immunodeficiency virus 1 gp160 peptide for presentation by major histocompatibility complex class I molecules.

Kozlowski S, Corr M, Takeshita T, Boyd LF, Pendleton CD, Germain RN, Berzofsky JA, Margulies DH.

J Exp Med. 1992 Jun 1;175(6):1417-22.

29.
30.

Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant.

Takahashi H, Nakagawa Y, Pendleton CD, Houghten RA, Yokomuro K, Germain RN, Berzofsky JA.

Science. 1992 Jan 17;255(5042):333-6.

PMID:
1372448
31.
32.

Peptides containing multideterminant clusters of human immunodeficiency virus envelope induce murine and human T-cell responses in diverse histocompatibility types.

Berzofsky JA, Pendleton CD, Clerici M, Ahlers J, Lucey DR, Putney SD, Shearer GM.

Trans Assoc Am Physicians. 1991;104:69-77. No abstract available.

PMID:
1845157
33.

Characterization of a helper T cell epitope recognized by mice of a low responder major histocompatibility type.

Kim JE, Kojima M, Houghten R, Pendleton CD, Cornette JL, DeLisi C, Berzofsky JA.

Mol Immunol. 1990 Oct;27(10):941-6.

PMID:
1700286
34.

An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes.

Hosmalin A, Clerici M, Houghten R, Pendleton CD, Flexner C, Lucey DR, Moss B, Germain RN, Shearer GM, Berzofsky JA.

Proc Natl Acad Sci U S A. 1990 Mar;87(6):2344-8.

Supplemental Content

Loading ...
Support Center